ignan bioavailability after flaxseed intervention: Impact of the intestinal microbiome
Not Applicable
- Conditions
- Healthy participants
- Registration Number
- DRKS00003609
- Lead Sponsor
- Technische Universität MünchenZentral Institut für Ernährungs- und LebensmittelforschungAbteilung BiofunktionalitätNachwuchsgruppe Intestinales Mikrobiom
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 10
Inclusion Criteria
Young adult healthy male subject (20 to 40 years old)
Exclusion Criteria
1) known allergy to flaxseeds; 2) Under- or overweight (BMI < 19 or > 27); 3) chronic diseases (inflammatory bowel diseases, type-1 and type-2 diabetes, dermatitis, food allergies); 4) medication within the last two months before the start of the study (antibiotics, anti-inflammatory drugs); 5) use of pre- or probiotics within the last two months before the start of the study; 6) participation to another clinical trial within the last two months before the start of the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) Fecal bacterial diversity and composition analysis (pyrosequencing and in situ hybridization); 2) Lignan concentrations in feces, blood and urine (high-pressure liquid chromatography).<br>Time points of measurement: d0, 1, 7 (before intervention), 14 (after intervention), 21
- Secondary Outcome Measures
Name Time Method Metabolite profiling in feces, blood and urine (mass spectrometry). Time points of measurement: d0, 1, 7 (before intervention), 14 (after intervention), 21